King's Research Portal

DOI:

[10.1016/j.eururo.2018.05.004](https://doi.org/10.1016/j.eururo.2018.05.004)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Bertolo, R., Autorino, R., Simone, G., Derweesh, I., Garisto, J. D., Minervini, A., Eun, D., Perdoni, S., Porter, J., Rha, K. H., Mottrie, A., White, W. M., Schips, L., Yang, B., Jacobsohn, K., Uzzo, R. G., Challacombe, B., Ferro, M., Sulek, J., ... Porpiglia, F. (2018). Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). *European Urology*.
<https://doi.org/10.1016/j.eururo.2018.05.004>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

**OUTCOMES OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CLINICAL T2
RENAL TUMORS: A MULTICENTER ANALYSIS (ROSULA* COLLABORATIVE
GROUP)**

Riccardo Bertolo^{1,2}, Riccardo Autorino^{3^}, Giuseppe Simone⁴, Ithaar Derweesh⁵, Juan D. Garisto²,
Andrea Minervini⁶, Daniel Eun⁷, Sisto Perdonà⁸, James Porter⁹, Koon Rha¹⁰, Alexander Mottrie¹¹,
Wesley M. White¹², Luigi Schips¹³, Bo Yang¹⁴, Kenneth Jacobsohn¹⁵, Robert G. Uzzo¹⁶,
Ben Challacombe¹⁷, Matteo Ferro¹⁸, Jay Sulek¹⁹, Umberto Capitanio²⁰, Uzoma Anele³, Gabriele Tuderti³,
Manuela Costantini³, Stephen Ryan⁵, Ahmet Bindayi⁵, Andrea Mari⁶, Marco Carini⁶, Aryeh Keehn⁷,
Giuseppe Quarto⁸, Michael Liao⁹, Kidon Chang¹⁰, Alessandro Larcher^{11,20}, Geert De Naeyer¹¹,
Ottavio De Cobelli¹⁸, Francesco Berardinelli¹³, Chao Zhang¹⁴, Peter Langenstroer¹⁵, Alexander Kutikov¹⁶,
David Chen¹⁶, Nicolo De Luyk¹⁷, Chandru P. Sundaram¹⁹, Francesco Montorsi²⁰, Robert J. Stein²,
Georges Pascal Haber², Lance J. Hampton³, Prokar Dasgupta¹⁷, Michele Gallucci⁴, Jihad Kaouk²,
Francesco Porpiglia¹

¹Dept of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy; ²Dept of Urology,
Cleveland Clinic, Cleveland, OH, USA; ³Division of Urology, VCU Health, Richmond, VA, USA; ⁴Dept of
Urology, "Regina Elena" National Cancer Institute, Rome, Italy; ⁵Department of Urology, UCSD Health
System, La Jolla, CA, USA; ⁶Department of Urology, University of Florence, Careggi Hospital, Firenze,
Italy; ⁷Dept. of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA;
⁸Division of Urology, Pascale Foundation, Institute for Cancer Research and Care, Napoli, Italy;
⁹Swedish Urology Group, Seattle, WA, USA; ¹⁰Urological Science Institute, Yonsei University College of
Medicine, Seoul, Korea; ¹¹Department of Urology, OLV Hospital, Aalst, Belgium; ¹²Dept of Urology,
University of Tennessee Medical Center, Knoxville, TN, USA; ¹³Department of Urology, Annunziata
Hospital, Dept. of Urology, Chieti, Italy; ¹⁴Dept. of Urology, Changhai Hospital, Shanghai, China;
¹⁵Dept. of Urology, Medical College Wisconsin, Milwaukee, WA, USA; ¹⁶Department of Urology, Fox
Chase Cancer Center, Philadelphia, PA, USA; ¹⁷Dept. of Urology, Guy's Hospital, King's College,
London, UK; ¹⁸Dept of Urology, IEO, Milan, Italy; ¹⁹Dept of Urology, Indiana University, Indianapolis,
IN, USA; ²⁰Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San
Raffaele, Milan, Italy

^Correspondence: Riccardo Autorino, MD, PhD, FEBU - Clinical Associate Professor of Urology, Virginia Commonwealth University - West Hospital, 7th floor, 1200 East Broad st, Richmond, VA, 23298, USA - Phone: +1 8046752169 - email: ricautor@gmail.com

***RObotic SURgery for LARge renal mass (ROSULA) project**

Abstract Word Count: 326; **Manuscript Word Count:** 2773

Keywords: *partial nephrectomy, robot-assisted; renal neoplasm; renal mass, clinical T2; outcomes*

ABSTRACT

Background: While partial nephrectomy (PN) represents the standard surgical management for cT1 renal masses, its role for cT2 tumors is controversial. Robotic assisted PN is being increasingly implemented worldwide.

Objective: To analyze perioperative, functional, oncological outcomes of robot-assisted PN (RAPN) for cT2 tumors.

Design, setting, and participants: Retrospective analysis of a large multicenter multi-national dataset of patients with non-metastatic cT2 masses treated with robotic surgery (ROSULA: RObotic SURgery for LARge renal mass).

Intervention: Robotic assisted PN (RAPN).

Outcome measurements and statistical analysis: Patients' demographics, lesion characteristics, perioperative variables, renal functional data, pathology and oncological data were analyzed. Univariable and multivariable regression analyses assessed the relationships with the risk of intra-/post-operative complications, recurrence and survival.

Results and limitations: 298 patients were analyzed. Median tumor size was 7.6 cm (7-8.5). Median RENAL score was 9 (8-10). Median ischemia time was 25 min (20-32). Median estimated blood loss was 150 ml (100-300). Sixteen patients had intraoperative complications (5.4%), whereas 66 (22.1%) had postoperative complications (5.0% were Clavien grade ≥ 3). Multivariable analysis revealed that lower RENAL score (OR 0.46, $p=0.021$) and confirmed pathological pT2 stage (OR 0.51, $p=0.001$) were protective against postoperative complications. 243 lesions (81.6%) were malignant. Twenty patients (8.2%) had positive surgical margins. Ten deaths and 25 recurrences/metastases occurred at a median follow-up of 12 months (5-35). At univariable analysis, higher pT stage was predictive of likelihood of recurrences/metastases ($p=0.05$). ANOVA test showed significant deterioration of renal function at discharge, while remaining stable over time at 1-yr follow-up. Main limitation of this study is the retrospective design.

Conclusions: RAPN in setting of select cT2 renal masses can be safely performed with acceptable outcomes. Further studies are warranted to corroborate our findings and to better define the role of robotic nephron-sparing for this challenging indication.

Patient summary: This report shows that robotic surgery can be used for safe removal of a large renal tumor in a minimally invasive fashion, maximizing preservation of renal function, and without compromising cancer control.

1. Introduction

Current guidelines recommend partial nephrectomy (PN) as the standard surgical treatment for clinical T1a renal tumors, whenever technically feasible [1, 2], given better renal functional preservation compared to radical nephrectomy (RN) [3]. However, for larger localized renal tumors, RN is still regarded as the reference standard, despite emerging data suggesting a potential role for a nephron-sparing approach in selected cases [4]. For T1b renal masses, PN was shown to provide to be not inferior to RN in terms of cancer control [5-7]. Recent reports, mainly limited to open surgery series, suggest that even in patients with larger masses (> 7 cm, clinical T2), PN does not compromise cancer-specific mortality [8-10].

With the diffusion of robotic daVinci surgery, experience with robot-assisted PN (RAPN) has exponentially grown over the last decade, and this has led to broaden the utilization of the procedure to more complex tumors. However, RAPN for clinical T2 renal masses represents a challenging intervention, and very few case series have been reported to date [11-16].

The aim of the present study was to analyze the perioperative, functional and oncological outcomes of RAPN for cT2 tumors in a large multi-institutional dataset (RObotic SUrgery for LARge renal mass – ROSULA project).

2. Materials and Methods

2.1. Study design

The ROSULA is a multi-center multi-national project including 22 robotic centers worldwide. A dataset of patients consecutively underwent robotic surgery either by radical or nephron sparing approach for $\geq$ cT2 renal masses was created. Institutional Review Board

approval or exempt was obtained at each Center. The purpose-built ROSULA database was queried for patients with non-metastatic cT2 renal masses who had undergone RAPN at 19 of participating institutions during the study period (July 2007 – Sep 2017) (**Suppl. Figure 1**).

The following parameters were collected:

- a. patients' baseline characteristics (age, gender, race, body mass index [BMI], ASA score, presence of diabetes mellitus, hypertension or preoperative chronic kidney disease [CKD] stage $\geq$ III, solitary kidney status, preoperative hemoglobin, serum creatinine and estimated Glomerular Filtration Rate, as calculated by the MDRD formula [17];
- b. tumor characteristics (side, clinical size, clinical stage according to TNM [18], cystic features, RENAL nephrometry score (tumor complexity was graded as low, moderate and high, RENAL score 4–6, 6–9 and 10–12, respectively [19]);
- c. perioperative variables (transperitoneal vs retroperitoneal approach, operative time, warm ischemia time, percentage of clamp-less and cold ischemia technique procedures, estimated blood loss [EBL], intra-operative complications [including transfusions], conversions, and postoperative complications [graded according to the Clavien-Dindo system [20] – complications $\geq$ grade III were considered as major], length of hospital stay and hemoglobin at discharge;
- d. pathology data (pathologic tumor size, pathologic stage according to TNM, tumor histology according to the 2004 World Health Organization criteria

[21], tumor grade according to Fuhrman [22], margin status, presence of sarcomatoid differentiation, presence of tumor thrombus).

- e. Functional data, including serum creatinine and eGFR at discharge and at 1, 6 and 12 postoperative months. Postoperative “early” (at discharge) acute renal injury (AKI) was defined according to the RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage kidney disease) criteria [23].
- f. Oncological data, including tumor recurrence, tumor metastasis, cancer-specific mortality.

2.2. Study objectives

Primary study endpoint was the assessment of surgical (perioperative) outcomes. In this regard, as a surrogate of surgical quality, a “trifecta” outcome was used, which included negative surgical margins, no perioperative complications, and WIT $\leq$ 25 minutes [24].

Secondary endpoints were the short term (1 year) functional and oncological outcomes.

2.3. Statistical analysis

Means + standard deviations (SD) were used to report variables with a normal distribution; medians and interquartile ranges (IQR) in case of variables with a non-normal distribution instead. Frequencies and proportions were used to report categorical variables. The means of continuous and categorical variables were compared by using the student T- and the Chi-square tests, respectively. ANOVA test was used to compare more than two groups.

Univariable and multivariable forward stepwise logistic regression analyses assessed the relationships of variables of interest with the risk of: (a) intraoperative complications, (b) overall postoperative complications, and (c) postoperative renal dysfunction as defined according to the RIFLE criteria.

Univariable analyses were used to test the effect of variables of interest on the probability of recurrences or metastases. Due to the small number of cancer-related deaths, the analysis was avoided for this outcome. Significance level was set at $p\text{-value} < 0.05$. Statistical analysis was performed using Statistic 8.0 Software (Tulsa, Oklahoma, US).

3. Results

Two-hundred ninety-eight patients who underwent RAPN for cT2 renal mass were included in the analysis. In **supplementary Table 1**, number of cases per Institution is provided. A trend towards a higher number of cases was observed during the study period (**Figure 1**). Patients' baseline characteristics are reported in **Table 1**. Median clinical tumor size was 7.6 (IQR: 7-8.5) cm. Median RENAL score was 9 (IQR: 8-10).

3.1. Surgical outcomes

Only 8.4% of the procedures were performed by retroperitoneal approach. Mean operative time was 163 ± 75 minutes. Twenty-two (7.4%) procedures were performed by clamp-less approach. Median ischemia time was 25 (IQR: 20-32) minutes, with 5% of procedures performed by cold ischemia technique. Median estimated blood loss (EBL) was 150 ml (100-300). Sixteen patients had intraoperative complications (5.4%). Fifteen patients received intraoperative blood transfusions (5%), and one conversion to RN occurred (0.3%), which was due to sticky fat possibly compromising the oncological efficacy in soft large

mass with high risk of rupture. The detailed list of perioperative data and complications is reported in **Table 2**. Sixty-two patients (20.8%) had postoperative complications. Among these, fifteen had a major (Clavien grade ≥ 3) complication (5%).

Median length of hospitalization was 4 days (3-5). At discharge, hemoglobin was significantly reduced with respect to baseline (13.8 ± 1.7 vs 10.4 ± 3.0 ; $p < 0.001$).

At univariable analysis, EBL and BMI were predictors of intraoperative complications ($p < 0.001$ and $= 0.001$, respectively). Clinical tumor size (< 0.001) and pT stage 3 vs 2 ($p = 0.003$) were predictors of postoperative complications. Multivariable logistic regression demonstrated that simple RENAL score (4-6) and non-pathological upstaging (pT2) were independently associated with a decreased risk of development of complications (OR 0.46, $p = 0.021$ and OR 0.51, $p = 0.001$, respectively).

3.2. Renal functional outcomes

ANOVA test showed significant deterioration of renal function at discharge (median decrease 17.5%, p -values < 0.001), while at 1-yr follow-up both SCr and eGFR were comparable to their discharge value ($p = 0.798$ and 0.159 , respectively) (**Supplementary Figure 2**). Out of 180 patients who had complete eGFR data preoperatively and at discharge, sixty-two patients (34.4%) experienced postoperative AKI (**Table 2**). On multivariate analysis, preoperative eGFR < 60 ml/min/1.73^{m2}, increasing clinical tumor size (every 1 cm), and preoperative diabetes mellitus were independent predictors of postoperative AKI (OR = 2.61, 1.98 and 5.13, $p < 0.001$, $= 0.009$ and 0.018 , respectively - **Table 3**).

3.3. Oncological outcomes

Pathology data are detailed in **Table 4**. Median size at final pathology was 7.4 cm (IQR 6.4-8.2). Most of the lesions were malignant ($n = 243$; 81.6%). Among malignant

1 lesions, 58 % were Fuhrman grade 1-2 (or without grading), and 42% Fuhrman grade 3-4. In
2 9 cases a sarcomatoid differentiation was found. Twenty patients (8.2%) had positive
3 surgical margins. Forty-two patients (17.2%) were down-staged to pT1a-b, whereas 93
4 (38.3%) were upstaged to pT3-4 at final pathology. Among the 63 patients who underwent
5 lymph-nodes dissection, only one patient had nodal involvement (pN1).

6 Twenty-five recurrences or progression to metastasis (actuarial progression rate:
7 10.3%) were observed and 2 deaths (0.7%) related to metastatic renal cancer occurred after a
8 median follow-up of 12 months.

9 At univariable Cox regression, pT3a pathological upstaging was the only significant
10 predictor of recurrence/metastasis ($p = 0.05$, **Figure 2A**); tumor thrombus, higher Fuhrman
11 grade (3-4) and sarcomatoid differentiation showed a trend towards significance (**Figure 2B**
12 and **Figure 3A, B**, respectively).

13 14 **3.4. Trifecta**

15 A “trifecta” outcome was achieved in 120 (49.4%) patients among the 243 patients
16 who had malignant lesions.

17 18 **4. Discussion**

19 To the best of our knowledge, this represents the largest series of RAPN for cT2 renal
20 masses to date. The present analysis relies on a robust sample from various Institutions
21 worldwide with an established robotic program, and it allows to draw some interesting
22 conclusions about this “extreme” indication for a robotic nephron-sparing approach. Overall,
23 we found RAPN for cT2 renal masses to be safely feasible, with acceptable perioperative and
24 functional outcomes.

1 In a recent systematic review, Mir et al found only 4 studies comparing PN to the
2 “gold standard” RN in the subset of patients with cT2 tumors. In their analysis, PN was
3 found to have significantly higher blood losses and likelihood of complication rates.
4 Nonetheless, these PN in these comparative analyses were performed with open and
5 laparoscopic, as opposed to robotic approach. [4].

6 Studies on robotic nephron-sparing surgery for larger masses remain quite sparse and
7 limited [11-14]. Malkoc et al. recently reported a single center study comparing a series of 54
8 robotic to 56 open partial nephrectomies for >7 cm renal tumors [15]. RAPN was found to be
9 superior to the open approach, but median ischemia time was above 30 minutes in both the
10 approaches. The incidence of overall complications was 18.5 % and 28.6 %, in favor of
11 robotic, with a major complications rate of 3.7 % and 12.5 %, respectively. Complications
12 rate of RAPN for highly complex renal masses were reported to be almost the same in a
13 recent prospective series by Porpiglia et al., with 23.8% and 4.8 of overall and major
14 complications, respectively [25].

15 Of note, the results from our multicenter study confirmed that even in case of cT2
16 renal tumors, the robotic approach allows for acceptable ischemia time (median 25 min) [26],
17 and complication rates (21% overall, 5% major complications). If data on complications are
18 slightly higher than what previously reported for RAPN [11-16], they appear to be
19 consistently lower to series reporting complications for T2 open PN [6, 15]. Our findings that
20 increasing tumor complexity and tumor size are predictive of postoperative complications are
21 consistent with recent reports from large national and institutional databases. [27, 28]. Our
22 reported Trifecta rate of 49.4% is lower than reports from series with small renal masses.
23 Nonetheless, given that predictors for Trifecta include increasing tumor complexity or size,

our findings are not surprising. Interestingly, our findings are similar to those of Abdel Raheem and co-workers published who reported a Trifecta rate of 37.5% when examining Trifecta rates in patients undergoing PN for complex renal masses [29].

Regarding the functional data, one-third of the patients experienced postoperative AKI, as assessed by RIFLE criteria [23]. Similar rates were reported in a large sample of PN procedures by Rajan et al [30]. AKI was found to correlate by baseline patient's factors like eGFR and diabetes, as also reported by others [31]. More interestingly, tumor size was also a predictor of postoperative AKI, which can be explained by larger excision of renal parenchyma. In this respect, Zhang et al reported that parenchymal mass reduction and ischemia both contribute to acute changes after PN, and while postoperative AKI is associated with suboptimal recovery, even patients with grade 2/3 AKI up to 90% of recovery can be expected [32]. In our analysis, while eGFR was found overall to be significantly reduced at 1 month postoperatively more than 15%, it remained stable over time, which is in line with previous findings [33].

Notably, a significant proportion of patients experienced up-staging to pT3a after PN. Up-staged pT3a patients had worsened recurrence/metastasis free survival across all clinical tumor stages after PN. In a recent single institution analysis, Mouracade and colleagues evaluated on more than 1000 patients with cT1 staged renal masses the perioperative morbidity, oncological outcome and predictors of pT3a upstaging after partial nephrectomy [34]. They found that male gender and R.E.N.A.L. score were preoperative predictors of upstaging. In our multicenter cohort, we had 70% of male patients and a median RENAL score of 9. In our study, while we noted several factors trending towards significance as

1 predictors for recurrence or metastases, none reached statistical significance. This is most
2 likely a limitation due to the short follow up of our cohort.

3 While the adoption of a nephron sparing approach for higher risk masses might be
4 concerning from an oncological standpoint, population-based studies suggest that even in
5 patients with adverse pathologic features, PN does not seem to compromise cancer-specific
6 mortality, and therefore the decision to perform a PN should mostly rely on the technical
7 feasibility [35]. In our series, the high pT3 staged tumors (33%) might be one explanation for
8 the 8% rate of positive surgical margins. Indeed, 10 patients (50%) who had positive surgical
9 margins were upstaged to pT3. Moreover, if one considers the open surgery literature
10 specifically regarding the larger masses, this rate compares favorably. Indeed, in a recent
11 review the range of positive surgical margins for these cases was found to be 0 to 31% [36].
12 In support of our data, in the Mouracade study pT3a tumors had 18.6% of positive surgical
13 margins rate [34]. Using the US National Cancer Database, Fero et al. reported an overall
14 increased rate of positive margins at 7.3%, driven by increasing use of minimally invasive
15 approaches, and not by higher clinical stage [37].

16 Moreover, in a multicenter retrospective survey, Bensalah and co-authors analyzed
17 111 patients with PSM, concluding that PSM status more likely occurs when surgery is
18 imperative, as could be the case of more complex renal lesions. In that study, PSM status did
19 not influence cancer-specific survival but it was associated with increased risk of recurrence
20 [38]. More recently, Khalifeh and colleagues found an 18-fold higher risk for recurrence in
21 case of PSM, after adjusting for multiple tumors, tumor size, tumor growth pattern and
22 pathological stage [39].

Concerning the oncological outcomes, our analysis showed an actuarial rate of 8.6% of recurrences or metastases, with 2 cancer-related deaths (0.7% actuarial cancer-specific mortality) occurred after a median follow-up of 12 months. Such findings could be read as satisfactory too. Indeed, even if there is still limited retrospective evidence about the oncological efficacy of PN for renal tumors larger than 7 cm, the available literature data reported in a recent review with follow-up range of 13.1 to 70 months showed 5-year progression-free survival and 5-year overall survival ranging from 71 to 92.5% and from 66 to 94.5%, respectively [36].

Our study is not devoid of limitations. First and foremost, the retrospective design accounts for some inherent biases, including patient selection and differences in surgical technique. It was beyond the scope of the present analysis to compare RAPN to the reference standard RN, and therefore a control arm was not considered. Also, the available follow-up of this cohort was limited (median 12 months), and it did not allow evaluating long term outcomes. One might argue that would be interesting to know how many cT2 renal masses were seen at these institutions during the time-period of the study to gauge the level of selection bias and to determine if most patients with cT2 masses offered robotic PN and how patients were ultimately selected for a robotic vs open partial approach. Unfortunately, we do not have this detailed information. The choice of one approach (robotic) versus the other (open) was at discretion of each surgeon. Having said that, the aim of the study was not to determine “practice patterns” of management of these large renal masses at participating institutions, but rather to report their experience with the robotic PN for this “extreme” indication. Concerning the evaluation of renal function, we concur that while the use of eGFR is a practical viable option, ideally a nuclear renal scan should be adopted [17].

1 However, this was not available for this study. Last, no centralized radiologic or pathologic
2 review was performed for the here reported cases.

3 Notwithstanding these limitations, this series represents the largest describing the
4 outcomes of mostly elective RAPN for large (clinical stage T2) renal masses in a “real-life”
5 scenario. On the other hand, these study findings may not be generalizable to the entire
6 urologic community, and they are reserved for experienced robotic surgeons/centers of
7 excellence. Even though cT1a and certainly cT1b tumors may be challenging for most, and
8 PN remains overall underused for these “standard” indications. Future definition of
9 maximum tumor threshold and more accurate preoperative staging are mandatory to optimize
10 the outcomes. Moreover, image-guidance technology could aid in expanding the role of
11 RAPN for these challenging indications [40].

12 13 **Conclusions**

14 RAPN in case of large renal masses can be safely performed with acceptable
15 outcomes. Further studies are warranted to corroborate our findings and to better define the
16 role of RAPN for this challenging indication. For the time being, the decision to proceed with
17 robotic nephron sparing surgery should be weighted based on the technical feasibility and
18 patient’s individualized competing risk of morbidity and cancer related events.

References

1. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol* 2015; 67:913–24.
2. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. *J Urol* 2009; 182:1271–9.
3. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol* 2011; 59:543–52.
4. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie M, Autorino R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. *EurUrol* 2017; 71: 606-617.
5. Weight CJ, Miller DC, Campbell SC, et al. The management of a clinical T1b renal tumor in the presence of a normal contralateral kidney. *J Urol* 2013; 189:1198–202.
6. Porpiglia F, Mari A, Bertolo R, et al. Partial Nephrectomy in Clinical T1b Renal Tumors: Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted Approach (the RECORD Project). *Urology*. 2016; 89:45-51.
7. Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. *BJU Int* 2012; 109:1457–62.

- 1 8. Kopp RP, Mehrazin R, Palazzi KL, et al. Survival outcomes after radical and partial
2 nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry
3 score. *BJU Int* 2014; 114:708–18.
- 4 9. Long CJ, Canter DJ, Kutikov A, et al. Partial nephrectomy for renal masses ≥ 7 cm:
5 technical, oncological and functional outcomes. *BJU Int* 2012; 109:1450–6.
- 6 10. Becker F, Roos FC, Janssen M, et al. Short-term functional and oncologic outcomes
7 of nephron-sparing surgery for renal tumours ≥ 7 cm. *Eur Urol* 2011; 59:931–7.
- 8 11. Ficarra V, Bhayani S, Porter J, et al. Robot-assisted partial nephrectomy for renal
9 tumors larger than 4 cm: results of a multicenter, international series. *World J Urol.*
10 2012; 30(5):665-70. doi: 10.1007/s00345-012-0943-9.
- 11 12. Brandao LF, Zargar H, Autorino R, et al. Robot-assisted partial nephrectomy for ≥ 7
12 cm renal masses: a comparative outcome analysis. *Urology* 2014; 84:602–8.
- 13 13. Gupta GN, Boris R, Chung P, Linehan WM, Pinto PA, Bratslavsky G. Robot-assisted
14 laparoscopic partial nephrectomy for tumors greater than 4 cm and high nephrometry
15 score: feasibility, renal functional, and oncological outcomes with minimum 1 year
16 follow-up.
- 17 14. Serni S, Vittori G, Frizzi J, et al. Simple enucleation for the treatment of highly
18 complex renal tumors: Perioperative, functional and oncological results. *Eur J Surg*
19 *Oncol.* 2015; 41(7):934-40.
- 20 15. Malkoc E, Ramirez D, Kara O, Maurice MJ, Nelson RJ, Caputo PA, Kaouk JH.
21 Robotic and open partial nephrectomy for localized renal tumors larger than 7 cm: a
22 single-center experience. *World J Urol.* 2017; 35(5):781-787.

16. Masson-Lecomte A, Yates DR, Bensalah K, et al. Robot-assisted laparoscopic nephron sparing surgery for tumors over 4 cm: operative results and preliminary oncologic outcomes from a multicentre French study. *Eur J Surg Oncol* 2013; 39:799–803.
17. Bertolo RG, Zargar H, Autorino R, et al. Estimated glomerular filtration rate, renal scan and volumetric assessment of the kidney before and after partial nephrectomy: a review of the current literature. *Minerva Urol Nefrol.* 2017 Dec;69(6):539-547.
18. Novara G, Ficarra V, Antonelli A, et al. Corrigendum to "Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?" [*Eur Urol* 2010; 58:588-95]. *Eur Urol.* 2011 Jan;59(1):182. doi: 10.1016/j.eururo.2010.10.017. Epub 2010 Oct 15. No abstract available.
19. Kutikov A, Smaldone MC, Egleston BL et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. *Eur Urol* 2011; 60: 241–8
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Surgery* 2004; 240:205-13.
21. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. *Eur Urol.* 2018 Jan 8. pii: S0302-2838(17)31064-3. doi: 10.1016/j.eururo.2017.12.018. [Epub ahead of print] Review. PubMed PMID:

- 1 22. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters
2 in renal cell carcinoma. *Am J Surg Pathol* 1982; 6:655–63.
- 3 23. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P and the ADQI workgroup.
4 Acute renal failure – definition, outcome measures, animal models, fluid therapy and
5 information technology needs: the Second International Consensus Conference of the
6 Acute Dialysis Quality Initiative (ADQI) Group. *Critical Care* 2004 Aug; 8(4):R204-
7 212.
- 8 24. Zargar H, Porpiglia F, Porter J, et al. Achievement of trifecta in minimally invasive
9 partial nephrectomy correlates with functional preservation of operated kidney: a multi-
10 institutional assessment using MAG3 renal scan. *World J Urol.* 2016 Jul;34(7):925-31.
- 11 25. Porpiglia F, Fiori C, Checcucci E, Amparore D, Bertolo R. Hyperaccuracy Three-
12 dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping
13 During Robot-assisted Partial Nephrectomy for Complex Renal Masses. *Eur Urol.* 2018
14 Jan 6. pii: S0302-2838(17)31095-3. doi: 10.1016/j.eururo.2017.12.027. [Epub ahead of
15 print]
- 16 26. Volpe A, Blute ML, Ficarra V, et al. Renal Ischemia and Function After Partial
17 Nephrectomy: A Collaborative Review of the Literature. *Eur Urol.* 2015 Jul;68(1):61-74.
18 doi: 10.1016/j.eururo.2015.01.025. Epub 2015 Feb 20. Review.
- 19 27. Winoker JS, Paulucci DJ, Anastos H, et al. Predicting Complications Following Robot-
20 Assisted Partial Nephrectomy with the ACS NSQIP(®) Universal Surgical Risk
21 Calculator. *J Urol.* 2017 Oct;198(4):803-809.

28. Zaid HB, Parker WP, Lohse CM, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Patient factors associated with 30-day complications after partial nephrectomy: A contemporary update. *Urol Oncol*. 2017 Apr;35(4):153.
29. Abdel Raheem A, Alatawi A, Kim DK, et al. Outcomes of high-complexity renal tumours with a Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) score of ≥ 10 after robot-assisted partial nephrectomy with a median 46.5-month follow-up: a tertiary centre experience. *BJU Int*. 2016 Nov;118(5):770-778.
30. Rajan S, Babazade R, Govindarajan SR et al. Perioperative factors associated with acute kidney injury after partial nephrectomy. *Br J Anaesth*. 2016 Jan;116(1):70-6.
31. Mamut AE, Violette PD, Rowe NE, Cui F, Luke PP. Measuring the impact of medical chronic kidney disease and diabetes mellitus on renal functional decline following surgical management of renal masses. *Urology*. 2016; 91:124-127
32. Zhang Z, Zhao J, Dong W, Remer E, Li J, Demirjian S, Zabell J, Campbell SC. Acute Kidney Injury after Partial Nephrectomy: Role of Parenchymal Mass Reduction and Ischemia and Impact on Subsequent Functional Recovery. *Eur Urol*. 2016; 69(4):745-52.
33. Porpiglia F, Fiori C, Bertolo R, et al. Long-term functional evaluation of the treated kidney in a prospective series of patients who underwent laparoscopic partial nephrectomy for small renal tumors. *Eur Urol*. 2012; 62(1):130-5.
34. Mouracade P, Kara O, Dagenais J, Maurice MJ, Nelson RJ, Malkoc E, Kaouk JH. Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors. *World J Urol*. 2017 Sep;35(9):1425-1433. doi: 10.1007/s00345-017-2004-x. Epub 2017 Feb 14

35. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, Shariat SF, Chun FK, Perrotte P, Graefen M, Karakiewicz PI. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. *Urology*. 2012; 80(2): 347-53.
36. Alanee S, Herberts M, Holland B, Dynda D. Contemporary Experience with Partial Nephrectomy for Stage T2 or Greater Renal Tumors. *Curr Urol Rep*. 2016 Jan;17(1):5.
37. Fero K, Hamilton ZA, Bindayi A, Murphy JD, Derweesh IH. Utilization and quality outcomes of cT1a, cT1b and cT2a partial nephrectomy: analysis of the national cancer database. *BJU Int*. 2017 Oct 15. doi: 10.1111/bju.14055. [Epub ahead of print]
38. Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. *Eur Urol*. 2010 Mar;57(3):466-71. doi: 10.1016/j.eururo.2009.03.048. Epub 2009 Mar 31.
39. Khalifeh A, Kaouk JH, Bhayani S, et al. Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind). *J Urol*. 2013 Nov;190(5):1674-9
40. Porpiglia F, Fiori C, Checcucci E, Amparore D, Bertolo R. Hyperaccuracy Three-dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping During Robot-assisted Partial Nephrectomy for Complex Renal Masses. *Eur Urol*. 2018 Jan 6. pii: S0302-2838(17)31095-3. doi: 10.1016/j.eururo.2017.12.027.

Figures' Legend

Figure 1. Chart showing the number of robot assisted partial nephrectomy (RAPN) during the study period.

Figure 2. Cumulative Proportion of Recurrence or metastasis (Kaplan-Meier curves) after stratification by A) pT stages according to TNM and B) presence of tumor thrombus (TT).

Figure 3. Cumulative Proportion of Recurrence or metastasis (Kaplan-Meier curves) after stratification by A) Fuhrman grade and B) presence of sarcomatoid pattern (sarc.).

Supplementary Figure 1. Study flow chart.

Supplementary Figure 2. Box and Whisker Plots showing Median, Inter-Quartile range (25-75%) and Minimum and Maximum values of the distribution (Min-Max) of A) Serum Creatinine (SCr) and B) estimated Glomerular Filtration Rate (eGFR). Overall ANOVA test showed a significant difference in SCr and eGFR (preoperative vs. postoperative, $p < 0.001$). Conversely, no differences were found among the postoperative values of both SCr and eGFR ($p = 0.798$ and 0.159 , respectively).